A Paradigm Shift: T Cells Gain Phagocytic Function via Specific Antigen Recognition
The research team engineered CD8+ Jurkat T cells to express SVAR16, a human TCR with intermediate-to-high 2D affinity for the SARS-CoV-2-derived epitope HLAA2:01–YLQ, using lentiviral transduction. Employing a Biomembrane Force Probe (BFP) system—an advanced micromanipulation technique—the team precisely controlled and imaged the interaction between these engineered T cells and microbeads coated with cognate pMHC (HLAA2:01–YLQ) or a control pMHC (HLA*A2:01–SL9 from HIV Gag).
The results were striking: upon contact with cognate pMHC-coated beads, the engineered CD8+ T cells formed conjugates within seconds, initiated phagosome formation within minutes, and fully internalized the beads in approximately 4 minutes—with consistent kinetic patterns across experiments. In stark contrast, no conjugation or phagocytosis was observed when the T cells interacted with control pMHC-coated beads over a 10-minute period. All six tested SVAR16-transduced T cell lines formed phagosomes within 3 minutes, and half completed full bead internalization, confirming that specific TCR-pMHC recognition, supported by CD8 co-receptors, is sufficient to drive T cell phagocytosis.
Antigen Density: A Critical Regulator of T Cell Phagocytic Efficiency
To further explore the factors governing this newly discovered T cell function, the researchers modulated the site density of pMHC on the bead surface (1245, 218, 75, and 27 pMHC/μm²) by adjusting coating protein concentrations. Their findings identified antigen site density as a key regulatory parameter: lower pMHC density reduced the proportion of T cells that formed phagosomes, delayed phagosome initiation, and completely abolished full engulfment at densities of 75 pMHC/μm² or lower. Only 1 out of 6 T cells achieved full phagocytosis at a density of 218 pMHC/μm², demonstrating that a minimum threshold of TCR-pMHC engagement is required for efficient T cell phagocytosis.
Mechanistic Insights and Translational Promise for Immunotherapy
Mechanistically, the study links TCR-pMHC-mediated phagocytosis to well-characterized T cell signaling pathways and mechanobiological regulation. TCR activation triggers signaling through the LAT–SLP-76–Vav1 complex, activating Rho family GTPases that drive actin polymerization—an essential process for pseudopod extension and bead engulfment. Intracellular Ca²⁺ flux, a critical mediator of T cell activation and cytoskeletal remodeling, is tightly coupled to this pathway, highlighting the integration of molecular signaling and mechanical forces in the process.
From a mechanobiological perspective, the phagocytic process involves dynamic mechanical stress on TCR-pMHC bonds: early-stage interactions rely on a small number of bonds to bear mechanical load, while pseudopod extension increases contact area and redistributes load—creating a fluctuating mechanical microenvironment at the immunological synapse. This insight suggests that engineering TCRs or CARs (chimeric antigen receptors) with favorable mechanical properties (e.g., high 2D affinity and catch-bond stability) could enable these engineered cells to maintain signaling under the high-shear, high-compression conditions of the solid tumor microenvironment—a major limitation of current CAR-T therapies.
For cancer immunotherapy, the discovery holds transformative potential:
- It empowers CD4+ T cells, traditionally considered helper cells, with direct killing capacity via phagocytosis of antigen-positive tumor cells, filling a critical gap in current T cell therapy.
- Phagocytic T cells can regulate antigen availability in the tumor microenvironment, preventing T cell exhaustion and modulating bystander T cell phenotypes to enhance local immune activation and tumor infiltration.
- It provides a new design principle for T cell engineering: tuning TCR-pMHC interactions and phagocytic function to develop more effective therapies for solid tumors, which account for the majority of cancer-related deaths worldwide.
Future Directions: From Cell Models to Clinical Application
While the study validates T cell phagocytosis in Jurkat cells—a widely used model for T cell signaling—the research team notes that primary CD4+ T cells differ from Jurkat cells in activation thresholds, metabolic state, and membrane elasticity. Future work will focus on engineering class I-restricted TCRs and CARs in primary CD4+ T cells to characterize phagocytic function under physiological conditions and across different T cell subsets. Additionally, targeted modulation of key signaling nodes (e.g., LAT–SLP-76–Vav1 complexes, Ca²⁺ flux) and mechanobiological optimization of TCR/CAR design will be key research priorities to translate this discovery into clinical practice.
